The ThinPrep Difference

HPV Testing with the ThinPrep Pap Test: Out of the Vial

The ThinPrep Pap Test is approved by the U.S. Food and Drug Administration (FDA) as a platform for HPV DNA testing directly from the ThinPrep Pap Test collection vial. A study conducted by the National Cancer Institute concluded that HPV testing is a viable method for determining which patients with borderline pap results are at highest risk for developing cancer. The ThinPrep Pap Test method is also approved/cleared for Chlamydia trachomatis (CT)/ Neisseria Gonorrhea (NG) and Trichomonas testing directly from the ThinPrep Pap Test collection vial.

The ThinPrep Pap Test is the preferred approach when liquid-based cytology is used.1-3


1. Richart R (moderator), Cox J, Twiggs L, Wilkinson E, Wright T. A sea change in diagnosing and managing HPV and cervical cancer - Part 1 (symposium). Contemporary Ob/Gyn. 2002;47:42-4,47-8,51-2,54,56.

2. Wright T, Cox J, Massad LS, Twiggs L, Wilkinson E. 2001 consensus guidelines for the management of women with cervical abnormalities. JAMA. 2002;287:2120-9.

3. Manos MM, et al. Identifying women with cervical neoplasia: Using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA. 1999;281:1605-10. For additional information on ASC-US management, please see ASCCP "Algorithms from the Consensus Guidelines for the Management of Women with Cervical Cytological Abnormalities."

See clinical guidelines on pap testing, HPV testing, and imaging technology.

Learn more

Educate your patients about pap testing and HPV.

Learn more

Privacy | Terms | Sitemap